AddLife

What AddLife does

AddLife AB is a Swedish publicly listed Life Science group operating under a decentralized holding-company model through approximately 85 wholly-owned operating subsidiaries across Europe. The company was spun off from Bergman & Beving in March 2016 and listed on Nasdaq Stockholm (ticker ADDLF), reporting FY2025 net sales of SEK 10,442 million, approximately 2,300 employees and adjusted EBITA margin of 12.1%.

Operations are organized into two business areas: Labtech (diagnostics, biomedical research and laboratory analysis serving hospital laboratories, academic research institutions and pharmaceutical companies) and Medtech (medical technology, assistive equipment and digital welfare/homecare solutions serving publicly funded healthcare systems, hospitals and social-care providers). The group does not develop core proprietary technology at the parent level; instead, it acquires and operates niche, market-leading distributors that sell specialized products including sequencing instruments and reagents from more than ten international suppliers, patient-positioning devices (e.g., Opitek), advanced coagulation diagnostics (CoaChrom), surgical solutions in urology/gynaecology/general surgery (BioSpectrum), pharmaceutical refrigeration systems (Pharmacold), welfare technology platforms (Hepro Response) and laboratory consumables (BonsaiLab, Euroclone, BioCat, Biolin Scientific).

Revenue is generated through B2B hardware and consumable sales to institutional buyers via direct field-sales forces operated by each subsidiary under its own brand, with pricing negotiated at the subsidiary level. The growth model combines modest organic expansion (3% organic growth in Q1 2026 excluding the divested UK endoscopy business) with disciplined acquisitions at multiples below 7x EV/EBITDA, funded by a balance sheet running at 2.3x net debt/EBITDA — well inside the 3.0x ceiling. Recent activity is heavy: four acquisitions closed in five months between December 2025 and April 2026 alongside a divestiture of the UK endoscopy business in December 2025, all consistent with portfolio rebalancing toward higher-margin advanced diagnostics and welfare technology.

Name

AddLife

Legal name

AddLife AB

Website

https://add.life

Company type

Public

Founded year

2016

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

AddLife AB is a Swedish-listed decentralized Life Science group operating ~85 subsidiaries across Europe that distribute medical technology, laboratory diagnostics, genomics/sequencing products and welfare technology to publicly funded healthcare systems, hospitals, research institutions and pharmaceutical companies.

Ownership category

akta.pro rank

Product category

Medical Technology and Laboratory Distribution

NAICS

Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers (423450)

SIC

Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

Durable Medical Equipment (DME) & Home Health Distribution (CRAOAHAF)

Keywords

• Medical technology distribution
• Laboratory products supply
• Diagnostic equipment sales
• Life science solutions
• Healthcare medtech products

Headquarters

HQ city

Stockholm

HQ country

Sweden

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Medtech Products and Services: Sale of medical technology products and services including assistive equipment, digital solutions for home care, surgical products, patient positioning devices, and welfare technology. The Medtech segment focuses on publicly funded healthcare, home care, and social care in Europe. Revenue from products (instruments and consumables) and services.
2. Labtech Products and Solutions: Sale of diagnostic products, biomedical research equipment, laboratory analysis instruments and services. The Labtech segment serves hospital laboratories, academic research, and pharmaceutical companies in Europe. Revenue streams include products, instruments, and services across two business units: Biomedical and Research, and Diagnostics.
3. Advanced/Genomics Products: Sales of sequencing-related products and services including instruments, reagents and software. Total sales of sequencing-related products reached approximately SEK 400 million in 2025. Market growth of 10-15% per year expected.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

AddLife is a European Life Science company that, through approximately 85 decentralized operating subsidiaries, supplies medical technology products and laboratory diagnostics solutions to healthcare providers, research institutions, and pharmaceutical companies. Its offerings span two business areas: Medtech (medical devices, assistive equipment, surgical products, and digital home-care solutions) and Labtech (diagnostic instruments, biomedical research equipment, laboratory reagents, and gene sequencing products from 10+ international suppliers). Revenue is generated primarily through product sales (instruments and consumables) with additional services revenue.

Product overview

AddLife is a European Life Science company with a decentralized business model, operating through approximately 85 subsidiaries organized into two main business areas: Medtech and Labtech. Medtech offers products and services in medical technology, assistive equipment, and digital solutions for home care, focusing on hospital and homecare segments. Labtech provides products, solutions and services in diagnostics, biomedical research, and laboratory analysis, serving hospital laboratories, academic research, and pharmaceutical companies. The company operates through acquired niche brands including CoaChrom Diagnostica (coagulation diagnostics), BioSpectrum (surgical solutions in urology/gynecology/general surgery), Opitek International (patient positioning devices), Pharmacold (refrigeration technology for pharmaceuticals), Euroclone (life sciences), BonsaiLab (advanced genomics), and Biolin Scientific (surface analysis). Products span gene sequencing, welfare technology platforms like Hepro Response, and various medical/laboratory equipment across Europe.

Differentiator

Problem solved

Functional benefit

Brands

• Medtech: Business area offering products and services in medical technology, assistive equipment and digital solutions for home care. Has two business units: Hospital and Homecare.
• Labtech

Products and services

• Medtech Business area offering products and services in medical technology, assistive equipment, and digital solutions for use in home care. Medtech has two business units - Hospital and Homecare - and focuses on publicly funded healthcare, home care, and social care in Europe.
• Labtech Business area providing products, solutions, and services in diagnostics, biomedical research, and laboratory analysis. Consists of two business units: Biomedical and Research, and Diagnostics, serving hospital laboratories, academic research, and pharmaceutical companies in Europe.
• Hepro Response A welfare technology platform that brings together different welfare technology solutions in a seamless service, developed for institutions, care and nursing homes, and people living at home. Includes medication support, digital follow-up at home, and digital supervision.
• Genomics and Gene Sequencing Solutions

Quantifiable outcome

• Adjusted EBITA margin improved to 12.1% in 2025 from 10.5% in 2023
• +3 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Multiple International Suppliers (10+)coreChannel Partner/ Reseller/ DistributorAddLife's subsidiaries serve as distributors for more than ten leading international suppliers in the genomics and sequencing space. These supplier relationships provide instruments, reagents, and software that subsidiaries then sell to customers in research, diagnostics, and healthcare across Scandinavia, Central/Eastern Europe, and Southern Europe. The suppliers include global manufacturers of sequencing equipment and related products.
• Josep Carreras InstituteminorStrategic or Co-development PartnerBonsaiLab, an AddLife subsidiary focused on advanced genomics in Spain and Portugal, collaborates with the Josep Carreras Institute to advance cancer research closer to patients. This partnership supports AddLife's strategy of investing in growing niche areas with strong partnerships.
• Local Partners (Sweden, Denmark, UK)minorChannel Partner/ Reseller/ DistributorHepro has worked with partners in Sweden, Denmark and England for many years through distribution partnerships. The company's solutions are already well-known in these markets through existing partners. With the establishment of own companies, Hepro intends to both further develop partnerships and come closer to the market through direct operations.

Scale indicators11 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Indutrade AB: Swedish serial acquirer of niche industrial technology and life-science businesses; same decentralized multi-subsidiary playbook, similar revenue and margin trajectory, and a public-market comparable for roll-up economics in Europe.
• Diploma PLC: UK-listed specialist distribution group acquiring niche technical and medical businesses; closest Western European peer to AddLife's roll-up, decentralised model with strong margin discipline.
• Beijer Alma AB: Swedish industrial and medical-technology distributor group with a multi-subsidiary model; overlaps AddLife on medical/industrial distribution and provides a small-cap comparable.
• Mölnlycke Health Care: Swedish-owned medtech group focused on wound care, surgical and prevention solutions; comparable to AddLife's Medtech division on customer base (hospitals, home care) and European distribution footprint.
• Boule Diagnostics AB: Swedish IVD/hematology diagnostics company serving hospital and clinical laboratories; comparable to AddLife Labtech in customer base, distribution model and product type.
• Lifco AB: Swedish holding company run by Carl Bennet that builds decentralized groups of niche leaders via perpetual bolt-ons; comparable in acquisition cadence and decentralized operating philosophy to AddLife.
• Addtech AB: Swedish technical-solutions distribution group spun off from the same Bergman & Beving parent; operates the same decentralized, acquisition-driven model across niche industrial markets in the Nordics and Europe — the closest structural analogue to AddLife.

Broad incumbents

• Bio-Rad Laboratories: U.S. life-science tools and clinical diagnostics company; comparable to AddLife Labtech on diagnostics, biomedical research and genomics-adjacent product exposure, though positioned as a manufacturer rather than distributor.
• Sartorius AG: German bioprocessing and life-science tools supplier with deep exposure to pharma/biotech customers; comparable to AddLife Labtech in single-use, filtration and genomics-adjacent segments, but at far larger scale.
• Getinge AB: Swedish incumbent in medical technology, surgical workflows and ICU; overlaps with AddLife Medtech in patient positioning and hospital solutions but is a much larger diversified manufacturer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UC_YiKbKavYICoTU37Y0C8pg
• LinkedInlinkedin.com/company/addlife-ab

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A26 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AddLife